Copyright © 2004 by the European Society of Cardiology.
Clinical research
Plasma homocysteine in obstructive sleep apnoea
a Division of Cardiovascular Disease, Mayo Clinic and Mayo Foundation, 200 1st St. SW, Rochester, MN 55901, USA
b University of Iowa, Iowa City, IA, USA
* Corresponding author. Tel.: +1-507-255-1144; fax: +1-507-255-7070
E-mail address: somers.virend{at}mayo.edu
Received 1 March 2004; revised 28 April 2004; accepted 18 May 2004 See page 1281 for the editorial comment on this article1
Abstract
Aims Whether increased homocysteine is one mechanism linking obstructive sleep apnoea (OSA) to cardiovascular abnormalities is unclear. We hypothesised that plasma homocysteine would be higher in OSA patients than in control subjects, would increase further during sleep, and decrease after treatment with continuous positive airway pressure (CPAP).
Methods and Results For study A, homocysteine was measured in 22 OSA patients and 20 controls first before sleep, then after 5 h of untreated OSA, and then in the morning after CPAP treatment. Homocysteine was similar in the OSA and control subjects at all three time points, and declined overnight in both groups (
, 
, respectively). To further assess this diurnal variation, we studied plasma homocysteine under a full-night protocol in 10 OSA patients and 12 controls (study B). Homocysteine was measured before sleep, in the morning after sleep, and at noon. Results in both OSA and control groups showed an overnight decline in homocysteine which was reversed by noon (repeated measures ANOVA: OSA, 
; controls, 
). Study C showed that disturbed sleep did not affect homocysteine levels in normal subjects.
Conclusion There is a significant diurnal variation in plasma homocysteine, so that homocysteine is lower in the morning after waking. Neither OSA nor disturbed sleep elicit acute or chronic changes in homocysteine.
Key Words: Homocysteine • Sleep apnoea • CPAP
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Obstructive sleep apnoea and plasma homocysteine: an overview
- Mikolaj Winnicki and Paolo Palatini
EHJ 2004 25: 1281-1283.[Extract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  C. Selmi, N. Montano, R. Furlan, C. L. Keen, and M. E. Gershwin Inflammation and Oxidative Stress in Obstructive Sleep Apnea Syndrome Experimental Biology and Medicine, December 1, 2007; 232(11): 1409 - 1413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Steiropoulos, V. Tsara, E. Nena, C. Fitili, M. Kataropoulou, M. Froudarakis, P. Christaki, and D. Bouros Effect of Continuous Positive Airway Pressure Treatment on Serum Cardiovascular Risk Factors in Patients With Obstructive Sleep Apnea-Hypopnea Syndrome Chest, September 1, 2007; 132(3): 843 - 851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ryan, G. M Nolan, E. Hannigan, S. Cunningham, C. Taylor, and W. T McNicholas Cardiovascular risk markers in obstructive sleep apnoea syndrome and correlation with obesity Thorax, June 1, 2007; 62(6): 509 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Olson and V. K. Somers Modulation of cardiovascular risk factors by obstructive sleep apnea. Chest, February 1, 2006; 129(2): 218 - 220. [Full Text] [PDF]
|
|
|
|
|
|
M. Can, S. Acikgoz, G. Mungan, T. Bayraktaroglu, E. Kocak, B. Guven, and S. Demirtas Serum cardiovascular risk factors in obstructive sleep apnea. Chest, February 1, 2006; 129(2): 233 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Svatikova, R. Wolk, M. J. Magera, A. S. Shamsuzzaman, B. G. Phillips, and V. K. Somers Obstructive sleep apnoea and plasma homocysteine: reply Eur. Heart J., October 2, 2005; 26(20): 2210 - 2211. [Full Text] [PDF]
|
|
|
|
|
|
L. Lavie and P. Lavie Obstructive sleep apnoea and plasma homocysteine Eur. Heart J., October 2, 2005; 26(20): 2210 - 2210. [Full Text] [PDF]
|
|